MHRA’s new ‘International Recognition Procedure’ – how does it shape up?
Web Exclusives
With great power comes great responsibility
AI in drug discovery has arrived but how can pharma use it as a force for good?
Mind over matter
Leveraging mobile voice recognition technology to safeguard mental health services
The PharmaTimes interview
A chat with Greg Flynn – Global President at Inizio Engage
Group therapy
Sharon King talks about her experience of bringing up a child with Batten disease and the team approach needed to develop gene therapies for rare diseases
Patient Partnership Index 2022
Celebrating top examples of partnerships between pharma companies and patient groups
Leipzig/Halle Airport region joins forces to attract investors
Airport and development agencies sign a cooperation agreement covering more than one federal
Will remote pharma GMP auditing cease after COVID?
Auditing activity is moving increasingly online but deeper analysis shows that not all clients are convinced
Adventure time
Alex Flynn was 36 when diagnosed with Parkinson’s in 2008 and has since raised around £400,000 in the last ten years
Why it’s time for a revolution in contraceptive medication
Deborah Stafford-Watson explores how new-era health brands are putting women first
Fixing the insights gap
Lance Hill, CEO of Within3, explores how pharma companies can address the life sciences insight gap
Transforming brain health
Dr Bjoern Schelter explores the role of technological innovation in transforming brain health
Increasing brand and commercial impact with modular content
A modular content strategy is rapidly emerging as the best practice for developing, reusing and delivering compliant digital content at scale with speed
De-risking new launches for biotech: the customer advantage
How does prioritising the customer lead to a more successful launch?
Impact of immunosuppressants on COVID-19 vaccine response
Dr Daniel Streetman considers whether immunosuppressants can reduce the response to COVID-19 vaccines
